Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**Ribosomal protein L32 pseudogene 16 (RPL32P16)** is a processed pseudogene belonging to the ribosomal protein L32 (RPL32) gene family. Pseudogenes such as RPL32P16 are sequences similar to their functional homologs but are generally not transcribed or translated into functional proteins. Most RPL32-related pseudogenes do not encode active proteins and do not have known molecular or disease associations. All available evidence indicates that RPL32P16 is noncoding and nonfunctional, and it is not considered a therapeutic target[1][3][7].\n\n**Notes:** \n- There are several pseudogenes in the RPL32 family, but only rare members (e.g., RPL32P3 in glioma biology[6]) have putative noncoding RNA regulatory roles, and these do *not* apply to RPL32P16 based on current published data.\n- All listings and major gene databases (GeneCards, Ensembl, OMIM, PubMed) confirm that RPL32P16 is annotated as a pseudogene and not as a protein-coding gene or target[1][3].
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L32 pseudogene 16 (RPL32P16).